- Home
- DH vs UPB Comparison
DH vs UPB Comparison
Compare DH & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DH
- UPB
- Stock Information
- Founded
- DH 2011
- UPB 2021
- Country
- DH United States
- UPB United States
- Employees
- DH N/A
- UPB N/A
- Industry
- DH Computer Software: Prepackaged Software
- UPB
- Sector
- DH Technology
- UPB
- Exchange
- DH Nasdaq
- UPB NYSE
- Market Cap
- DH 518.7M
- UPB 581.0M
- IPO Year
- DH 2021
- UPB 2024
- Fundamental
- Price
- DH $4.41
- UPB $10.81
- Analyst Decision
- DH Hold
- UPB Strong Buy
- Analyst Count
- DH 11
- UPB 4
- Target Price
- DH $6.15
- UPB $56.50
- AVG Volume (30 Days)
- DH 705.9K
- UPB 417.5K
- Earning Date
- DH 02-26-2025
- UPB 02-14-2025
- Dividend Yield
- DH N/A
- UPB N/A
- EPS Growth
- DH N/A
- UPB N/A
- EPS
- DH N/A
- UPB N/A
- Revenue
- DH $255,846,000.00
- UPB $2,207,000.00
- Revenue This Year
- DH $2.59
- UPB N/A
- Revenue Next Year
- DH N/A
- UPB N/A
- P/E Ratio
- DH N/A
- UPB N/A
- Revenue Growth
- DH 3.97
- UPB 82.10
- 52 Week Low
- DH $3.19
- UPB $10.36
- 52 Week High
- DH $10.62
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- DH 57.04
- UPB N/A
- Support Level
- DH $3.91
- UPB N/A
- Resistance Level
- DH $4.09
- UPB N/A
- Average True Range (ATR)
- DH 0.21
- UPB 0.00
- MACD
- DH 0.01
- UPB 0.00
- Stochastic Oscillator
- DH 74.01
- UPB 0.00
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.